Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)

Myotonic Dystrophy 1 Clinical Trial

— SwallowDM1  

Official title:

A Multidimensional Profile of Dysphagia in People Living With Myotonic Dystrophy Type 1 (plwDM1)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05865483
• Other study ID #: 153848
• Status: Recruiting
• Start date: July 3, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: May 2024
• Source: University College, London
• Contact: Jodi Allen, MRes
• Phone: 07760324254
• Email: jodi.allen.21[@]ucl.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to learn about swallowing difficulties (dysphagia) in patients living with myotonic dystrophy type 1 (DM1). The main questions it aims to answer are:

• whether the size and structure of the muscles involved in swallowing differ to those without the disease

• how the size and structure of muscles may associate with swallowing function and swallowing symptoms in this group.

Participants will undergo a range of tests including:

• Ultrasound (US) assessment of the muscles involved in swallowing

• An x-ray swallowing study (known as videofluoroscopy)

• Assessment of swallowing symptoms, including questionnaires

• Assessments of mobility, activity and breathing

• Assessments of quality of life and wellbeing

Description:

This study will explore swallowing difficulties (dysphagia) caused by Myotonic Dystrophy Type 1 (DM1). Dysphagia causes food, drink and saliva to travel onto the lungs (aspiration) and can lead to pneumonia. Aspiration pneumonia is frequent and accounts for over 40% of deaths in DM1. Dysphagia also causes fear and anxiety which can lead to permanent lifestyle changes.

A better understanding of dysphagia in DM1 will improve our assessment and treatment and reduce its life-changing consequences. This research aims to define the dysphagia profile of people with DM1 (pwDM1) across the domains of structure, function, experience, and wellbeing by:

1. Investigating the size and structure of muscles involved in swallowing in patients with and without DM1.

2. Exploring how muscle size and structure are associated with i) swallowing function and ii) symptoms

3. Exploring how swallowing function is associated with i) symptoms, ii) patient and caregiver wellbeing and iii) other aspects of DM1 such as walking and breathing.

People aged 18+ with a confirmed diagnosis of DM1 will be invited to take part. Approximately 90 pwDM1 will be recruited. They will undergo a battery of tests including:

• Ultrasound (US) assessment of the muscles involved in swallowing

• An x-ray swallowing study (known as videofluoroscopy)

• Assessment of swallowing symptoms, including questionnaires

• Assessments of mobility, activity and breathing

• Assessments of quality of life and wellbeing

A sub-group of 20 pwDM1 will also undergo magnetic resonance imaging (MRI) of the muscles involved in swallowing to examine in detail the changes in seen on ultrasound. Approximately 60 people without DM1 will act as a control group for the US assessments. Primary caregivers of those with DM1 will be invited to complete a wellbeing questionnaire.

Data will be analysed using statistical methods and findings will be used to develop clinical practice recommendations for the assessment and treatment of dysphagia in DM1.

This study is part of an NIHR-funded clinical doctoral research fellowship (CDRF) and will take place at The National Hospital for Neurology and Neurosurgery (NHNN) in London. The maximum timescale for the study from opening recruitment to data collection of the final participant is 18 months (approx. 1st April 2023 - 30th September 2024).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 195
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Participants with DM1

Inclusion:

• =18 years of age

• genetically confirmed of DM1

• able to eat & drink at least five sips of liquid by mouth at one time.

Exclusion:

• any condition or treatment other than DM1 that potentially influences swallowing muscle composition or function (e.g., a history of stroke or throat cancer).

• any patients who are pregnant

• patients with congenital or childhood DM1

• patients who are not able to eat or drink anything by mouth.

Related Conditions & MeSH terms

• Deglutition Disorders
• Dysphagia, Oropharyngeal
• Myotonic Dystrophy
• Myotonic Dystrophy 1

Locations

Country	Name	City	State
United Kingdom	The National Hospital for Neurology & Neurosurgery, University College London Hospitals	London

Sponsors (4)

Lead Sponsor	Collaborator
University College, London	Myotonic Dystrophy Support Group, United Kingdom, National Institute for Health Research, United Kingdom, The National Brain Appeal, The National Hospital for Neurology and Neurosurgery

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001 Feb 13;56(3):336-40. doi: 10.1212/wnl.56.3.336. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Swallowing muscle (geniohyoid) size		16 months
Primary	Swallowing muscle (geniohyoid) structure		16 months
Secondary	Association between muscle (size and structure) and dynamic swallowing assessment (VFSS)		16 months
Secondary	Association between muscle (size and structure) and strength (Iowa Oral Performance Instrument & bite-force)		16 months
Secondary	Association between muscle (size and structure) and swallowing speed (timed water swallow test & timed test of mastication)		16 months
Secondary	Association between muscle (size and structure) and patient symptoms (Sydney Swallow Questionnaire & SWAL-QOL)		16 months